- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Priority Health, Arine Partner to Optimize Medication Management
Priority Health has chosen Arine, the medication intelligence company, as its partner in a value-based care endeavor that strives to optimize members' health outcomes.
Grand Rapids, Michigan — Wanting to identify the top medication management program for its members—encompassing medication therapy, reduced costs, and improved health outcomes—Priority Health in November chose Arine, the medication intelligence company, as its partner in this value-based care endeavor.
Arine’s artificial intelligence (AI) capabilities will enable the nonprofit health plan to continue providing optimal care to its members while also striving for top quality ratings for several CMS’ Part C and D Star measures. In particular, Arine’s AI has the ability to pinpoint safe and effective, individualized, medication regimens by examining clinical, socioeconomic, and behavioral data.
“Priority Health is committed to improving health outcomes for our members and reducing costs,” said Christina Barrington, vice president of pharmacy programs at Priority Health. “Through this partnership, our members will continue receiving the care they need, lower their prescription costs and receive personalized medication advice.”
AI in Health Care: Balancing Governance, Innovation, and Trust
September 2nd 2025In this conversation with Reuben Daniel, associate vice president of artificial intelligence at UPMC Health Plan, we dive into how UPMC Health Plan builds trust with providers and members, discuss challenges of scaling AI effectively, and hear about concrete examples of AI's positive impact.
Listen
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
